Dana Callow will be speaking at the @DTRA Annual Meeting in Boston November 8th as part of an Investor Panel discussing PE, late-stage VC, early-stage VC, and Strategic Investments. This conversation will be very timely given our current economic environment, and our ecosystem including a range of companies from early through IPO. Join us as we gather leading visionaries in decentralized research and clinical trials to share ideas, develop lasting connections, and create new bonds over our shared mission to make patient-focused research accessible to everyone. #decentralizedclinicaltrials #DTRA2022
Read Full Release
SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that management will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28.
Roy Smythe, M.D, SomaLogic’s Chief Executive Officer is scheduled to participate in two panel discussions.
Proteomics “Everything You Wanted to Know, But Were Afraid to Ask”
Executive Panel Discussion at 10:15 a.m. Eastern Time
CEOs from Spatial Biology/Proteomics
Executive Panel Discussion at 1:00 p.m. Eastern Time
Read Full Release
Boston Millennia is pleased to announce the sale of our portfolio company, Forefront Telehealth, Inc. to Access TeleCare, a company focused on behavioral health, in a cash and stock transaction.
Forefront is a leading provider of virtual behavioral health solutions across the care continuum for seniors and other vulnerable adults. For over ten years, Forefront has provided the highest quality telepsychiatry and teletherapy care for patients in hospitals, long-term care, and home health settings.
Access TeleCare, (prior to this transaction known as SOC Telehealth) is the country’s largest provider of acute and specialty telemedicine, Access TeleCare works with hospitals, outpatient clinics, long-term care facilities, home health companies, and physician practices to provide telemedicine services in neurology, behavioral health, hospitalist medicine, pulmonary and critical care, maternal-fetal medicine, infectious disease, cardiology, nephrology, and endocrinology. BMP IV will maintain a position in the merged company, as their roll-up approach is consistent with BMP’s Core Company, “buy and build” strategy which we have implemented successfully for many years.
Read Full Release
KAID Health, an AI-powered health care data analysis and provider engagement platform, announced the results of a study that validates the potential utility of its Natural Language Processing (NLP) technology to improve provider efficiency and care quality. The peer-reviewed “doctor vs. artificial intelligence” paper found that KAID Health’s NLP technology greatly aligned with the clinician reviewers in completing a pre-operative checklist, and further was able to identify 16.6% of instances where the presence or absence of a specific condition was not found by the anesthesiologist. The research study was undertaken at UCSD’s Department of Anesthesiology, Division of Perioperative Informatics.
Read Full Release
Walgreens announced today their new clinical trial business will partner with BMP portfolio company Pluto Health. Pluto Health's multi-layered, smart care coordination service that unifies siloed health information from multiple places (such as medical records, social determinants of health, insurance claims and more) within 30 minutes will enhance the patient experience. The Pluto Health team evaluates patient health information with the recommended clinical care guidelines and social determinants of health data to identify and close any potential gaps in care. This helps ensure every patient receives the best possible care through up-to-date screenings, vaccinations and other health interventions, such as clinical research as a care option.
Read Full Release
SomaLogic, a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy. As part of the agreement, OncoHost will license SomaLogic’s SomaScan® Platform to develop proteomics tests for its PROphet® diagnostic system, designed to predict patient response to immunotherapy treatments and provide strategies to overcome treatment resistance. The collaboration reflects SomaLogic’s commitment to leveraging its industry leading assay capabilities in the development of high-plex proteomic diagnostic tests.
Read Full Release
BMP Managing General Partner, Dana Callow and Partner Jessica Federer will both chair panels at this year's DIA Global Annual Meeting in Chicago. Dana will host a forum "Accelerating Innovation Through Investing". This forum delves into the state of strategic investments from both pharmaceutical venture teams and institutional investors, exploring best practices to collectively advance research and care. Jessica will host a forum " Where Are we Really on Data Interoperability?". This session explores the current status of interoperability and data collaborations while giving insights into the challenges we currently face, and the value still left to be realized. We hope if you will be at DIA you will join us for two interesting discussions.
Read Full Release
BMP portfolio company, COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer. In her new role, she will spearhead efforts to drive broader adoption of real-world data by the life sciences industry to safely accelerate the speed of development and reduce the cost of life-saving cancer drugs. Sasu will also prioritize strategic provider and clinical research partnerships that will support evidence-based standards of care to improve patient outcomes, build health equity for all cancer patients, and drive down costs of cancer care.
Sasu joined COTA in April of 2021 as chief strategy officer and has already started building momentum for the company. She brought extensive experience in senior leadership roles at notable life sciences companies such as Johnson & Johnson and Bristol Myers Squibb.
Read Full Release
Boston Millennia Partners IV is pleased to announce its investment in Pluto Health as part of a growth equity financing round. Pluto Health is an early stage spin out of Duke University improving health care delivery and research. Pluto delivers treatment plans from curated recommendations to close health gaps to access to research, through their proprietary data interoperability and clinical intelligence platform.
Read Full Release
Boston Millennia Partners IV is pleased to announce its investment in Huma.AI as part of a growth equity financing round. Huma.AI is an early-stage, knowledge automation company for the life sciences industry. The Company’s central business is a unified, question-and-answer-based Natural Language Processing (NLP) platform that generates commercial and clinical insights using structured and unstructured data sources. The platform can answer complex questions through the simultaneous analysis of multiple siloed data sets, both public and private. The Company’s customizable SaaS offering can be deployed to address numerous use cases including: competitive intelligence on drug development pipelines, clinical trial design, and post-market surveillance. The company has contracts with over ten top-tier pharma clients.
Read Full Release
